Evista (raloxifene) reduces the risk of MI and stroke in postmenopausal women

A new analysis suggests that Evista (raloxifene) reduces the risk of MI and stroke in postmenopausal women.

This "selective estrogen" has some advantages for preventing or treating osteoporosis in postmenopausal women.

Both Evista and estrogen increase bone density.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote